CymaBay Therapeutics Company Profile (NASDAQ:CBAY)

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

CymaBay Therapeutics Inc. (NASDAQ:CBAY) announced its quarterly earnings data on Thursday, May, 11th. The company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.27) by $0.07. The firm had revenue of $4.79 million for the quarter. View CymaBay Therapeutics' Earnings History.

4 brokers have issued 1 year price objectives for CymaBay Therapeutics' shares. Their forecasts range from $6.50 to $8.00. On average, they anticipate CymaBay Therapeutics' share price to reach $7.17 in the next twelve months. View Analyst Ratings for CymaBay Therapeutics.

Here are some recent quotes from research analysts about CymaBay Therapeutics stock:

• 1. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (4/3/2017)
• 2. HC Wainwright analysts commented, " Recall, on December 7, CymaBay initiated an open-label, dose-ranging Phase 2 study (NCT02955602) of seladelpar (MBX-8025) in about 36 patients with primary biliary cholangitis (PBC) who are not adequately responding to, or are intolerant of, ursodeoxycholic acid (UCDA). Notably, the study sites are located in U.S., Canada, Germany and the U.K. Per protocol, patients are randomized to either 5 mg or 10 mg for 8 weeks. Based on review of the safety and efficacy of the 8 week data, new patients are then enrolled to receive 25 mg of seladelpar for 8 weeks. We also point out that the study incorporates an extension phase where patients are able to continue treatment for a total of 26 weeks, thus allowing for dose adjustments. In this trial, the primary endpoint is the reduction of alkaline phosphate (ALP) from baseline. Preliminary results from the first two cohorts (5 mg and 10 mg) are expected in early 3Q17 (likely July), with data readout of the third cohort (25 mg) anticipated by year end. Ahead of this important, near-term value inflection, we affirm our Buy rating on CBAY shares and raise our price target to $7." (3/27/2017)
• 3. Piper Jaffray Companies analysts commented, "CymaBay ended 2016 with cash of $17 million, and subsequently CymaBay received $5 million upfront from Kowa in January and raised net proceeds of $9.2 million in February bringing pro forma cash to ~$31 million. CymaBay will report Phase II data on 5mg and 10mg seladelpar in primary biliary cholangitis (PBC) in 3Q:17 followed by 25mg seladelpar data in 4Q:17. We will look for ALP reduction with enhanced liver safety following 3 transaminase elevations at higher doses in the prior study. Encouraging preclinical data for seladelpar in NASH could lead to a pre-IND meeting with the FDA in 2Q:17. CymaBay has partnered Phase III-ready arhalophenate with Kowa in the U.S., and could partner in Europe. We reiterate our Overweight rating and are increasing our price target to $6.50 from $5 by adding value for seladelpar in NASH." (3/24/2017)

CymaBay Therapeutics saw a drop in short interest during the month of June. As of June 15th, there was short interest totalling 367,834 shares, a drop of 32.6% from the May 31st total of 545,881 shares. Based on an average daily trading volume, of 315,066 shares, the short-interest ratio is currently 1.2 days. Currently, 1.5% of the shares of the stock are short sold.

Some companies that are related to CymaBay Therapeutics include Corbus Pharmaceuticals Holdings (CRBP), Minerva Neurosciences (NERV), GlycoMimetics (GLYC), Akebia Therapeutics (AKBA), Merus N.V. (MRUS), Ovid Therapeutc (OVID), Chimerix (CMRX), Circassia Pharmaceuticals PLC (CIR), AVEO Pharmaceuticals (AVEO), TOCAGEN INC (TOCA), Ardelyx (ARDX), Clearside Biomedical (CLSD), Immune Design Corp. (IMDZ), Catalyst Pharmaceuticals (CPRX), Cempra (CEMP), DURECT Corporation (DRRX), Zymeworks (ZYME) and Stemline Therapeutics (STML).

CymaBay Therapeutics' management team includes the folowing people:

• Robert James Wills Ph.D., Chairman of the Board
• Sujal Shah, Interim President, Interim Chief Executive Officer, Chief Financial Officer
• Charles A. McWherter Ph.D, Senior Vice President, Chief Scientific Officer
• Daniel Menold, Vice President - Finance, Principal Financial Officer, Principal Accounting Officer
• Kirk Rosemark, Vice President - Regulatory Affairs and Quality Assurance
• Pol F. Boudes M.D., Chief Medical Officer
• Robert Booth Ph.D., Director
• Caroline Loewy, Director
• Evan A. Stein M.D. Ph.D., Director
• Paul F. Truex, Director

CymaBay Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Versant Venture Management LLC (3.65%), Vanguard Group Inc. (2.86%), Boxer Capital LLC (2.70%), Omega Fund Management LLC (1.05%), Renaissance Technologies LLC (0.81%) and Geode Capital Management LLC (0.59%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Charles Mcwherter, Emster Kurt Von, Robert James Wills and Sujal Shah. View Institutional Ownership Trends for CymaBay Therapeutics.

CymaBay Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Vanguard Group Inc., Renaissance Technologies LLC, Geode Capital Management LLC, TFS Capital LLC, Acadian Asset Management LLC and ClariVest Asset Management LLC. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Charles Mcwherter, Emster Kurt Von, Robert James Wills and Sujal Shah. View Insider Buying and Selling for CymaBay Therapeutics.

Shares of CymaBay Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CymaBay Therapeutics stock can currently be purchased for approximately $5.50.